{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:32:59Z","timestamp":1790429579121,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.atherosclerosis.2016.02.016","type":"journal-article","created":{"date-parts":[[2016,2,14]],"date-time":"2016-02-14T08:21:58Z","timestamp":1455438118000},"page":"142-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The ubiquitin-activating enzyme E1 as a novel therapeutic target for the treatment of restenosis"],"prefix":"10.1016","volume":"247","author":[{"given":"Zhexue","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingbao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib1","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.jacc.2014.02.545","article-title":"Current treatment of in-stent restenosis","volume":"63","author":"Alfonso","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I","article-title":"Molecular mechanisms in intimal hyperplasia","volume":"190","author":"Newby","year":"2000","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11883-014-0401-9","article-title":"Pathophysiology of acute coronary syndrome","volume":"16","author":"Santos-Gallego","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCRESAHA.109.208801","article-title":"Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease","volume":"106","author":"Willis","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib5","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0735-1097(02)02564-0","article-title":"Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes","volume":"40","author":"Herrmann","year":"2002","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cardiores.2003.09.033","article-title":"The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended","volume":"61","author":"Herrmann","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrm2673","article-title":"Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways","volume":"10","author":"Schulman","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib8","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.cdd.4401702","article-title":"The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle","volume":"12","author":"Hershko","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2009-07-231191","article-title":"The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma","volume":"115","author":"Xu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib10","doi-asserted-by":"crossref","first-page":"e1000131","DOI":"10.1371\/journal.pgen.1000131","article-title":"E1 ubiquitin-activating enzyme UBA-1 plays multiple roles throughout C. elegans development","volume":"4","author":"Kulkarni","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/ATVBAHA.108.162362","article-title":"CCN1 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model","volume":"28","author":"Matsumae","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib12","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1073\/pnas.1015312108","article-title":"Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways","volume":"108","author":"Chou","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/ATVBAHA.110.203356","article-title":"CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration","volume":"30","author":"Shimoyama","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s001340100882","article-title":"Dexamethasone inhibits stimulation of pulmonary endothelins by proinflammatory cytokines: possible involvement of a nuclear factor kappa B dependent mechanism","volume":"27","author":"Dschietzig","year":"2001","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib15","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib16","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/cr.2007.89","article-title":"Andrographolide inhibits NF-kappaBeta activation and attenuates neointimal hyperplasia in arterial restenosis","volume":"17","author":"Wang","year":"2007","journal-title":"Cell Res."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2008.09.005","article-title":"A\u00a0novel antioxidant 3,7-dihydroxy-isoflav-3-ene (DHIF) inhibits neointimal hyperplasia after vessel injury attenuating reactive oxygen species and nuclear factor-kappaB signaling","volume":"204","author":"Kanellakis","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1124\/jpet.107.127407","article-title":"Acetylbritannilactone inhibits neointimal hyperplasia after balloon injury of rat artery by suppressing nuclear factor-{kappa}B activation","volume":"324","author":"Liu","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib20","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jacc.2008.06.045","article-title":"Possible dual role of ubiquitin-proteasome system in the atherosclerotic plaque progression","volume":"52","author":"Di Filippo","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib21","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1161\/01.CIR.0000045664.75269.A5","article-title":"Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-beta","volume":"107","author":"Redondo","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/diabetes.54.3.811","article-title":"Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a smad2-dependent mechanism","volume":"54","author":"Redondo","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib23","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0735-1097(00)01018-4","article-title":"Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty","volume":"36","author":"Roque","year":"2000","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib24","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1161\/01.CIR.99.16.2164","article-title":"Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle","volume":"99","author":"Gallo","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(02)07751-6","article-title":"Overcoming restenosis with sirolimus: from alphabet soup to clinical reality","volume":"359","author":"Poon","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jacc.2012.01.073","article-title":"Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. cypher stent in primary PCI for acute myocardial infarction) trial","volume":"60","author":"Hofma","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib27","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.jacc.2006.01.073","article-title":"Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment","volume":"47","author":"Marfella","year":"2006","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib28","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.ATV.0000232501.08576.73","article-title":"Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis","volume":"26","author":"Versari","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/med.20111","article-title":"Proteasome inhibitors: poisons and remedies","volume":"28","author":"Meiners","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14628840510011234","article-title":"The ubiquitin-proteasome system\u2013micro target for macro intervention?","volume":"7","author":"Herrmann","year":"2005","journal-title":"Int. J. Cardiovasc. Interv."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib31","first-page":"256","article-title":"Ubiquitin expression in atherosclerotic lesions of wistar fatty and wistar lean rats","volume":"21","author":"Igarashi","year":"1994","journal-title":"Artery"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib32","first-page":"1077","article-title":"Effects of proteasome and calpain inhibitors on the structural reorganization and proliferation of vascular smooth muscle cells in primary culture","volume":"79","author":"Thyberg","year":"1999","journal-title":"Lab. Investig."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0008-6363(96)00220-9","article-title":"Polyubiquitin is a new phenotypic marker of contractile vascular smooth muscle cells","volume":"33","author":"Adam","year":"1997","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/hc0402.102951","article-title":"Ubiquitin-proteasome pathway as a new target for the prevention of restenosis","volume":"105","author":"Meiners","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib35","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib36","doi-asserted-by":"crossref","first-page":"34696","DOI":"10.1074\/jbc.M802210200","article-title":"Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome","volume":"283","author":"Chou","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2006040333","article-title":"EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells","volume":"18","author":"Ying","year":"2007","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0092-8674(00)81375-6","article-title":"Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death","volume":"87","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/bjp.2008.115","article-title":"Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells","volume":"154","author":"Wu","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib40","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1126\/science.1149200","article-title":"Cancer proliferation gene discovery through functional genomics","volume":"319","author":"Schlabach","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/cvr\/cvp333","article-title":"On to the road to degradation: atherosclerosis and the proteasome","volume":"85","author":"Herrmann","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib43","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.atherosclerosis.2016.02.016_bib44","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leuk. Lymphoma"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T12:21:06Z","timestamp":1537014066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016300594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":44,"alternative-id":["S0021915016300594"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.016","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ubiquitin-activating enzyme E1 as a novel therapeutic target for the treatment of restenosis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}